Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,796 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05356741RecruitingPhase 1/Phase 2
Study drug VIR-5818 with and without pembrolizumab
This early trial tests whether VIR-5818 given through a vein is safe and whether it works better when combined with pembrolizumab. It’s for adults with HER2-positive cancers that are locally advanced or spread, and the study checks safety, side effects, and early signs of effect.
Duarte, CaliforniaAges 18 years+ - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT07250477RecruitingPhase 2
Guided immunotherapy for advanced lung cancer
This trial tests whether using a blood test to guide treatment can improve outcomes for people with advanced non-small cell lung cancer who are starting immunotherapy for the first time. Participants will receive standard immunotherapy tailored to their individual risk profile.
Chico, CaliforniaAges 18 years+ - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06416410RecruitingPhase 3
Combination targeted therapy for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hefei, AnhuiAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Gilbert, ArizonaAges 18 years+ - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT06775678RecruitingPhase 2
Spatial fragmentation plus low-dose radiation for resistant lung cancer
This study tests whether combining a special type of radiation (spatial fragmentation) with low-dose radiation can help people whose lung cancer stopped responding to immunotherapy and chemotherapy. If you are eligible, you may receive a new treatment approach to try to shrink the tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,796 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.